General MedicationsSUBCUTANEOUSStandard
VOXZOGO
VOSORITIDE
Standard Dose
0.4MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview VOXZOGO is listed in Drugs@FDA under application 214938 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient VOSORITIDE Form and strength POWDER;SUBCUTANEOUS - 0.4MG/VIAL Sponsor BIOMARIN PHARM Submission history Latest submission status date: 2024-11-04 00:00:00.
Structured Monograph
Clinical summary
Approval overview VOXZOGO is listed in Drugs@FDA under application 214938 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient VOSORITIDE Form and strength POWDER;SUBCUTANEOUS - 0.4MG/VIAL Sponsor BIOMARIN PHARM Submission history Latest submission status date: 2024-11-04 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.